País: Estados Unidos
Língua: inglês
Origem: NLM (National Library of Medicine)
NORGESTIMATE (UNII: C291HFX4DY) (norgestimate - UNII:C291HFX4DY), ETHINYL ESTRADIOL (UNII: 423D2T571U) (ethinyl estradiol - UNII:423D2T571U)
Xiromed, LLC.
NORGESTIMATE
NORGESTIMATE 0.180 mg
PRESCRIPTION DRUG
Tri-Estarylla (norgestimate and ethinyl estradiol) Tablets are indicated for use by females of reproductive potential to prevent pregnancy [see CLINICAL STUDIES (14)] . Tri-Estarylla is indicated for the treatment of moderate acne vulgaris in females at least 15 years of age, who have no known contraindications to oral contraceptive therapy and have achieved menarche. Tri-Estarylla should be used for the treatment of acne only if the patient desires an oral contraceptive for birth control [see CLINICAL STUDIES (14)]. Tri-Estarylla is contraindicated in females who are known to have or develop the following conditions: - A high risk of arterial or venous thrombotic diseases. Examples include women who are known to: Smoke, if over age 35 [see BOXED WARNING and WARNINGS AND PRECAUTIONS (5.1)] Have deep vein thrombosis or pulmonary embolism, now or in the past [see WARNINGS AND PRECAUTIONS (5.1)] Have inherited or acquired hyper coagulopathies [see WARNINGS AND PRECAUTIONS (5.1)] Have cerebrovascular
Tri-Estarylla (norgestimate and ethinyl estradiol tablets, USP) is available in blisters containing 28 tablets as follows: Each blister card contains 21 active tablets and 7 inactive tablets. 7 white (active) tablets are round, debossed with SZ on one side and T2 on the other side and contains 0.18 mg of norgestimate and 0.035 mg of ethinyl estradiol . 7 light blue (active) tablets are round, debossed with SZ on one side and T3 on the other side and contains 0.215 mg of norgestimate and 0.035 mg of ethinyl estradiol . 7 blue (active) tablets are round, debossed with SZ on one side and T4 on the other side and contains 0.25 mg of norgestimate and 0.035 mg of ethinyl estradiol . 7 green (inert) tablets are round, debossed with SZ on one side and J1 on the other side. NDC 70700-121-85, Carton containing three blister cards.
Abbreviated New Drug Application
TRI-ESTARYLLA- NORGESTIMATE AND ETHINYL ESTRADIOL XIROMED, LLC. ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE TRI-ESTARYLLA SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR TRI-ESTARYLLA. TRI-ESTARYLLA (NORGESTIMATE AND ETHINYL ESTRADIOL, USP) TABLETS, FOR ORAL USE INITIAL U.S. APPROVAL: 1989 WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS _SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING._ • • RECENT MAJOR CHANGES Contraindications. Pregnancy (4) 06/2023 INDICATIONS AND USAGE Tri-Estarylla (norgestimate and ethinyl estrdiol tablets) is a combinations of norgestimate, a progestin, and ethinyl estradiol, and estrogen, indicated for use by females of reproductive potential to prevent pregnancy. (1.1) Tri-Estarylla is indicated for the treatment of moderate acne vulgaris in females at least 15 years of age, who have no known contraindications to oral contraceptive therapy and have achieved menarche. Tri-Estarylla should be used for the treatment of acne only if the patient desires an oral contraceptive for birth control. (1.2) DOSAGE AND ADMINISTRATION Take one tablet daily by mouth at the same time every day. (2.1) Take tablets in the order directed on the blister pack. (2.1) Do not skip or delay tablet intake. (2.1) DOSAGE FORMS AND STRENGTHS Tri-Estarylla (norgestimate and ethinyl estradiol) tablets, USP consists of 28 round, biconvex, coated tablets in the following order (3): 7 white tablets each containing 0.180 mg norgestimate and 0.035 mg ethinyl estradiol 7 light blue tablets each containing 0.215 mg norgestimate and 0.035 mg ethinyl estradiol 7 blue tablets each containing 0.250 mg norgestimate and 0.035 mg ethinyl estradiol 7 dark green tablets (inert) CONTRAINDICATIONS A high risk of arterial or venous thrombotic diseases (4) Liver tumors or liver disease (4) Undiagnosed abnormal uterine bleeding (4) Breast cancer (4) Co-administration with Hepatitis C drug combinations containing ombitasvir/parit Leia o documento completo